IRWD (Ironwood Pharmaceuticals) Shiller PE Ratio: (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IRWD Ironwood Pharmaceuticals Inc IRWD
65 GF Score
Price $4.29
GF Value $4.64
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Ironwood Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ironwood Pharmaceuticals  (NAS:IRWD) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ironwood Pharmaceuticals Shiller PE Ratio Related Terms


Ironwood Pharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Ironwood Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ironwood Pharmaceuticals Shiller PE Ratio Chart

Ironwood Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ironwood Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IRWD vs TLRY, AQST, EOLS: Shiller PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ironwood Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ironwood Pharmaceuticals Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ironwood Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ironwood Pharmaceuticals's Shiller PE Ratio falls into.


IRWD
65GF Score
Ironwood Pharmaceuticals Inc IRWD
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ironwood Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ironwood Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Ironwood Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.31/333.9520*333.9520
=0.310

Current CPI (Jun. 2026) = 333.9520.

Ironwood Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.230 241.428 -0.318
201612 -0.090 241.432 -0.124
201703 -0.360 243.801 -0.493
201706 -0.300 244.955 -0.409
201709 -0.220 246.819 -0.298
201712 0.080 246.524 0.108
201803 -0.290 249.554 -0.388
201806 -0.320 251.989 -0.424
201809 -1.140 252.439 -1.508
201812 -0.100 251.233 -0.133
201903 -0.380 254.202 -0.499
201906 0.080 256.143 0.104
201909 0.130 256.759 0.169
201912 0.300 256.974 0.390
202003 0.020 258.115 0.026
202006 0.160 257.797 0.207
202009 0.210 260.280 0.269
202012 0.270 260.474 0.346
202103 0.250 264.877 0.315
202106 2.390 271.696 2.938
202109 0.340 274.310 0.414
202112 0.250 278.802 0.299
202203 0.210 287.504 0.244
202206 0.210 296.311 0.237
202209 0.280 296.808 0.315
202212 0.270 296.797 0.304
202303 0.250 301.836 0.277
202306 -6.840 305.109 -7.487
202309 0.090 307.789 0.098
202312 -0.010 306.746 -0.011
202403 -0.030 312.332 -0.032
202406 -0.010 314.175 -0.011
202409 0.020 315.301 0.021
202412 0.020 315.605 0.021
202503 -0.230 319.799 -0.240
202506 0.140 322.561 0.145
202509 0.230 324.800 0.236
202512 -0.010 324.054 -0.010
202603 0.240 330.213 0.243
202606 0.310 333.952 0.310

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Ironwood Pharmaceuticals (IRWD) Overvalued in 2026?

Based on GuruFocus' analysis, Ironwood Pharmaceuticals stock appears to be undervalued. The current stock price of $4.29 is trading 7.5% below its estimated GF Value™ of $4.64. GuruFocus considers Ironwood Pharmaceuticals to be Fairly Valued.

Key valuation signals for IRWD:

  • Shiller PE Ratio:
  • GF Value™: $4.64 vs. price of $4.29 (7.5% below fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the IRWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ironwood Pharmaceuticals Business Description

Other Exchanges I76:Germany
Address 100 Summer Street, Suite 2300, Boston, MA, USA, 02110
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
65GF Score

Get the complete analysis for IRWD

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.29
Price
$4.64
GF Value